US equities |
SPCX $167.10 ▲+5.12% NVDA $236.19 ▲+0.96% MU $1,063.22 ▼-1.09% TSLA $377.63 ▲+1.90% MSFT $524.95 ▲+1.43% SNDK $1,707.75 ▼-0.71% INTC $117.13 ▼-1.84% META $742.69 ▲+2.01%
FinancialContent

Articles published by BeiGene, Ltd.

< Previous 1 2 3 Next >
News headline image
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Nasopharyngeal Cancer
From BeiGene, Ltd.
Via Business Wire
Tickers ONC
News headline image
BeiGene Presents Pioneering Cancer Research at ASCO 2025 – Redefining Treatment Across Hematology and Solid Tumors
From BeiGene, Ltd.
Via Business Wire
Tickers ONC
News headline image
BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation
From BeiGene, Ltd.
Via Business Wire
Tickers ONC
News headline image
BeiGene to Present at the RBC Capital Markets Global Healthcare Conference
From BeiGene, Ltd.
Via Business Wire
Tickers ONC
News headline image
BeiGene Announces First Quarter 2025 Financial Results and Business Updates
From BeiGene, Ltd.
Via Business Wire
Tickers ONC
News headline image
U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene
From BeiGene, Ltd.
Via Business Wire
Tickers ONC
News headline image
BeiGene to Announce First Quarter 2025 Financial Results on May 7
From BeiGene, Ltd.
Via Business Wire
Tickers ONC
News headline image
BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program
From BeiGene, Ltd.
Via Business Wire
Tickers ONC
News headline image
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy
From BeiGene, Ltd.
Via Business Wire
Tickers ONC
News headline image
BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates
From BeiGene, Ltd.
Via Business Wire
Tickers ONC
News headline image
BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27
From BeiGene, Ltd.
Via Business Wire
Tickers ONC
News headline image
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene to Present at Upcoming Investor Conferences
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene to Present at the Jefferies London Healthcare Conference
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene Mourns Death of Beloved Board Member Donald Glazer
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene Receives Positive CHMP Opinions for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
News headline image
Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors
From BeiGene, Ltd.
Via Business Wire
Tickers BGNE
< Previous 1 2 3 Next >